Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
0.738(c) 0.7328(c) 0.71(c) 0.6983(c) 0.7065(c) Last
704 136 1 197 806 643 576 502 921 382 693 Volume
+4.24% -0.70% -3.11% -1.65% +1.17% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 6,27x
Capi. / Sales2014 2,76x
Capitalization 98,7 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.The... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
01/05 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
01/04 PROTALIX BIOTHERAPEUTICS : Reports Positive Interim Data from Phase II Clinical ..
01/03 PROTALIX BIOTHERAPEUTICS : Reports Positive Interim Data from Phase II Clinical ..
01/03 PROTALIX BIOTHERAPEUTICS : Reports Positive Interim Data From Phase II Clinical ..
01/02 PROTALIX BIOTHERAPEUTICS : Gains on "Positive" Phase II Results
01/02 Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical..
2017 PROTALIX BIOTHERAPEUTICS' : PRX-102 Granted Orphan Drug Designation by the Europ..
2017 PROTALIX BIOTHERAPEUTICS INC : Wired News - Protalix BioTherapeutics Granted Orp..
2017 Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by th..
2017 PROTALIX BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Fin..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 824%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC7.38%99
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423
LONZA GROUP0.76%20 876
INCYTE CORPORATION-4.65%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 275